Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital
**Patient Story: CAR-T Therapy Brings New Hope for Lymphoma Patients – A Case from a Chinese Hospital**
Patient Story
In the field of cancer treatment, China has achieved groundbreaking success with CAR-T cell therapy, especially in treating relapsed or refractory lymphoma. Today, we share the story of one patient whose life was transformed through this revolutionary treatment provided by a leading hospital in China.
## Patient Journey: Diagnosed with Complex Lymphoma
Mr. Li, a 59-year-old man from China with a long history of hypertension, noticed swelling in his right elbow in September 2019. As the swelling worsened over the following months, he sensed that something was seriously wrong. After evaluations at multiple hospitals, he was diagnosed with diffuse large B-cell lymphoma (DLBCL). Complicating matters, genetic testing revealed that he had TP53 and MYD88 mutations, making his case particularly challenging.
At a local hospital, Mr. Li underwent a series of standard treatments, including cyclophosphamide, prednisone, ibrutinib, and rituximab. Initially, his condition improved, but six months later, he began experiencing discomfort in his lower abdomen. Testing confirmed that his lymphoma had relapsed and spread. Multiple rounds of second-line, third-line, and even fourth-line treatments were unable to control his disease.
## Last Hope: China’s CAR-T Therapy Shows Remarkable Effect
With few options left, Mr. Li reached out to our Advanced Medicine in China team as his last hope. Our expert team took on his case, and he was promptly admitted to begin CAR-T cell therapy in China. This innovative treatment involves reprogramming the patient’s own immune cells to recognize and attack cancer cells. Chinese experts created a precise treatment plan for Mr. Li and initiated CAR-T cell infusion.
The treatment response was remarkable. Although Mr. Li experienced a brief period of fever and mild neutropenia following therapy, these symptoms resolved quickly with supportive care. He avoided severe side effects often associated with CAR-T therapy, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). A month later, his follow-up scan revealed complete remission (CR). The Chinese CAR-T treatment not only successfully controlled his high-risk lymphoma but also spared him many of the common side effects.
## Expert Insights: A New Option for High-Risk Patients
This case demonstrates the significant effectiveness of China’s CAR-T therapy for patients with high-risk genetic mutations. Our team’s expert professor noted that patients with TP53 mutations, like Mr. Li, often respond poorly to standard first-line treatments but may achieve substantial improvement through CAR-T therapy. For high-risk patients such as Mr. Li, especially those with dual-expression and relapse within 12 months, early CAR-T treatment could yield greater benefits. CAR-T therapy in China may result in prolonged bone marrow suppression, which requires careful monitoring and supportive care based on the patient’s prior chemotherapy history and individual response.
China’s CAR-T therapy is bringing new hope for lymphoma patients around the world. It not only paves a new path in treatment options but also broadens our understanding of lymphoma treatment. By giving patients renewed hope for recovery, we look forward to this technology enabling lasting remission for even more lymphoma patients and offering a brighter future ahead.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #RRLymphoma #ChineseMedicalAdvances #Immunotherapy #PatientSuccess #Oncology #HopeForCancer #MedicalBreakthrough #CancerResearch #China
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)**
**Patient Story | Chinese CAR-T Therapy: An Inspiring Journey of Changing Fate for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)**
DLBCL
#CAR-T #DLBCL #Lymphoma #CARTtherapy #RRDLBCL #Patientstory #CD19
In the field of cancer treatment, China has made remarkable strides in CAR-T cell therapy, especially in the fight against relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). Today, we will share the story of a patient whose fate was transformed by this revolutionary treatment at a leading hospital in China.
**The Patient’s Struggle and the Introduction of CAR-T Therapy**
Mr. Wang, a 45-year-old patient from China, was diagnosed with R/R DLBCL. After undergoing the standard first-line R-CHOP chemotherapy, his cancer unfortunately relapsed. He then tried an alternative chemotherapy regimen, but the disease continued to progress. The relentless development of the lymphoma took a severe toll on his physical and mental health, and he and his family were urgently seeking a more effective solution.
At the point of near despair, Mr. Wang reached out to the Advanced Medicine In China team and received a potential solution at a renowned cancer center within the team. The experts introduced him to the possibility of CAR-T cell therapy. This cutting-edge treatment, gaining increasing attention within China’s medical field, offered a glimmer of hope.
**The Treatment Process and the Expertise of the Medical Team**
Before beginning CAR-T therapy, Mr. Wang underwent a comprehensive series of evaluations and preparations. An experienced medical team of oncologists, hematologists, and immunologists meticulously planned every step of the treatment. They explained the procedure in detail to Mr. Wang and his family, addressed their concerns, and ensured they fully understood the process.
The treatment began with the collection of Mr. Wang’s own T cells. These cells were then carefully modified in an advanced laboratory to express a chimeric antigen receptor (CAR) capable of specifically recognizing the CD19 antigen on lymphoma cell surfaces. Once the CAR-T cells were ready, they were infused back into Mr. Wang. Throughout the treatment, the medical team closely monitored his condition around the clock, prepared to manage any potential side effects, as these are a known risk of CAR-T therapy.
**Overcoming Challenges and Achieving Success**
In the days following the CAR-T cell infusion, Mr. Wang experienced some expected side effects, including fever and mild fatigue. The medical team, well-versed in managing CAR-T-related toxicities, promptly implemented appropriate medication and supportive care measures. They adjusted the treatment plan as needed to ensure Mr. Wang’s comfort and safety while maximizing the efficacy of the CAR-T cells.
Miraculously, within just one month of the infusion, Mr. Wang’s symptoms began to significantly improve. His tumor markers started to decrease, and follow-up scans showed a noticeable reduction in the size of lymphoma lesions. By the third month, he achieved partial remission (PR), and to everyone’s delight, by the sixth month, he reached complete remission (CR). This was not only a victory for Mr. Wang but also a testament to the power of Chinese CAR-T therapy and the expertise of the medical team. The hospital’s advanced facilities, combined with the doctors’ in-depth knowledge and experience, enabled them to navigate the complexities of CAR-T treatment and guide Mr. Wang toward recovery.
**Ripple Effects and Future Hope**
Mr. Wang’s story is just one of many success cases within China’s CAR-T treatment program. His experience brings hope not only to patients within China but also to countless others around the world with R/R DLBCL. It showcases the potential of China’s CAR-T cell therapy to offer new life for those who have exhausted traditional treatment options.
As China continues to invest in research and development in the field of CAR-T therapy, and as more hospitals and medical teams gain proficiency in its application, the future looks increasingly hopeful. Through ongoing efforts to optimize treatment protocols, manage side effects more effectively, and expand the accessibility of this life-saving therapy, Chinese CAR-T therapy will have a growing impact on the global fight against cancer.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #RRLymphoma #ChineseMedicalAdvances #Immunotherapy #PatientSuccess #Oncology #HopeForCancer #MedicalBreakthrough #CancerResearch #China
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL)
### APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL)
CNSL
#CAR-T #CNSL #ASCT #APBMT2024 #CARTtherapy #CentralNervousSystemLymphoma #Lymphoma #RRCNSL #APBMT
In the treatment of relapsed or refractory central nervous system lymphoma (R/R CNSL), Chinese CAR-T therapy is pioneering new directions worldwide. Conventional treatments for this disease have shown limited effectiveness, particularly when autologous stem cell transplantation (ASCT) fails, leaving patients facing the dual challenges of relapse and drug resistance. However, recent research from a team of Chinese medical experts has demonstrated that CAR-T therapy shows remarkable efficacy in patients with R/R CNSL, bringing hope to the global fight against central nervous system tumors.
### CAR-T Therapy for ASCT-Failed Patients: Breakthroughs in Safety and Efficacy
At the 29th Annual Congress of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT 2024), a team of Chinese medical experts shared their research results. CAR-T therapy was administered to 11 patients with R/R CNSL who had previously failed ASCT. By using individualized chemotherapy regimens to reduce tumor burden as a bridge to CAR-T therapy, they achieved a 3-month objective response rate (ORR) of 100%, and a 1-year progression-free survival (PFS) rate close to 90%. Most notably, in terms of safety, no patients experienced grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), making the treatment more manageable.
### Facing Challenges and Exploring Future Directions
Although ASCT has been regarded as a consolidative treatment strategy for CNSL, some patients still relapse post-transplant and develop resistance to chemotherapy. Dr. Hu Kai’s team’s research shows that CAR-T therapy remains highly effective and safe for ASCT-failed CNSL patients, offering new hope for patients with chemotherapy resistance. However, to further optimize CAR-T applications, the Chinese medical team continues to explore more individualized approaches, particularly in areas such as timing of treatment, reducing intracranial tumor burden, and improving overall efficacy.
### Research Data Supporting the Efficacy of Chinese CAR-T Therapy
The study included 11 patients with an average age of 58, all of whom had parenchymal brain involvement and received CAR-T therapy following ASCT failure. Post-treatment data further confirmed the efficacy and safety of Chinese CAR-T therapy: the 3-month complete remission rate (CRR) was 100%, and the 1-year PFS rate reached 87.5%. By combining tumor-reducing chemotherapy with CAR-T cell therapy, the Chinese medical team successfully extended patients’ progression-free survival time and overall survival, highlighting the tremendous potential of Chinese CAR-T therapy in treating R/R CNSL.
### Conclusion
This innovative study showcases China’s cutting-edge advancements in CAR-T therapy, especially in high-risk CNSL patients. The efforts of the Chinese medical team not only provide better treatment options for CNSL patients globally but also demonstrate China’s leadership in the global CAR-T research arena.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #ChinaMedicalResearch #Immunotherapy #OncologyBreakthrough
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma(DLBCL) Patient Achieve Complete Remission
### Beacon of Hope: China’s CAR-T Therapy Helps a TP53-Deficient Diffuse Large B-Cell Lymphoma Patient Achieve Complete Remission
DLBCL
#CAR-T #CancerTreatment #Lymphoma #DLBCL #PrecisionMedicine
In an inspiring treatment case, a 38-year-old Chinese male patient with TP53-deficient Diffuse Large B-cell Lymphoma (DLBCL) achieved complete remission through Chinese CAR-T cell therapy. This remarkable outcome has sparked excitement about the potential and efficacy of China’s CAR-T therapy for treating relapsed and refractory lymphomas.
Patient Treatment Journey
This Chinese patient was diagnosed with non-germinal center subtype DLBCL with TP53 gene deletion in March 2023, and his condition was assessed as high-risk. This genetic factor often complicates prognosis. The patient initially underwent treatments including R-CHOP and R-DA-EPOCH regimens, achieving partial remission (PR). Despite completing autologous stem cell transplantation (ASCT), his disease unfortunately progressed two months later, indicating that ASCT alone was insufficient for sustained remission, and the disease was on the brink of relapse.
Personalized Application of Chinese CAR-T Therapy
In desperation, the patient turned to our Advanced Medicine in China team for assistance. Under the guidance of lymphoma experts experienced in this treatment, the medical team decided to apply Chinese CAR-T cell therapy as a solution. Following a comprehensive assessment, including a detailed analysis of the patient’s medical history and genetic profile, a personalized treatment plan was devised. To further control the disease, the patient received localized retroperitoneal radiotherapy in January 2024, followed by the infusion of Chinese CAR-T cells in February after pretreatment with the FC regimen. Remarkably, just one month after the CAR-T cell infusion, the patient tolerated the therapy well and achieved complete remission (CR). This outcome not only halted disease progression but enabled the patient to return to work and resume a normal life.
Expert Interview with the Advanced Medicine in China Team
The team’s expert highlighted that this case involved relapsed refractory DLBCL, with TP53 deletion adding a higher risk of recurrence. ASCT alone was insufficient for sustained remission, making CAR-T a more effective option. Despite the greater treatment challenges, Chinese CAR-T therapy proved ideal for this high-risk relapsed case. The doctor advised that, when feasible in primary healthcare settings, Chinese CAR-T should be considered as an early intervention option. Research data supports the effectiveness of Chinese CAR-T in second-line therapy compared to standard ASCT.
Overall Advantages of Chinese CAR-T Therapy
This successful case is not isolated; it demonstrates China’s growing expertise and capabilities in CAR-T cell therapy. China has been at the forefront of research and clinical application in this field, committed to improving outcomes for lymphoma patients. The Chinese medical community takes a comprehensive approach to CAR-T therapy, prioritizing personalized medicine and tailoring treatment plans based on each patient’s unique genetic and clinical characteristics. For instance, advanced genetic testing enables doctors to identify specific mutations, such as P53 deletion, and adjust treatment strategies accordingly. When conventional chemotherapy and targeted drugs have limited efficacy, CAR-T cell therapy is increasingly being used as a viable alternative. Furthermore, Chinese hospitals continuously optimize treatment protocols. The pretreatment regimen prior to CAR-T cell infusion is meticulously designed to create an optimal therapeutic environment in the patient’s body. This not only removes barriers for the proliferation and effective functioning of CAR-T cells but also minimizes potential side effects. In this case, the patient’s positive response to the therapy was partly due to the carefully crafted pretreatment regimen.
Global Significance of China’s Experience
As the world seeks innovative cancer treatment solutions, China’s success with CAR-T cell therapy for lymphoma patients provides valuable insights. The combination of advanced medical technology, personalized treatment strategies, and comprehensive patient support offers beneficial lessons for the global fight against lymphoma and other cancers. With ongoing research and accumulating clinical experience, the future of Chinese CAR-T cell therapy holds great promise, bringing hope not only to patients in China but to patients worldwide.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#ChinaMedicalInnovation #Immunotherapy #GeneTherapy #Oncology #TP53 #CompleteRemission #AdvancedMedicine #GlobalHealth
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
How to Choose Among Similar CAR-T Therapies?
**How to Choose Among Similar CAR-T Therapies?**
Currently, there are multiple CAR-T products targeting the same antigen available on the market, which can make it difficult for patients to decide which one to choose.
Experts recommend selecting a therapy based on the treatment target. It is generally advisable to prioritize approved products, as they have been validated, providing better assurance of safety and efficacy. For example, CD19-targeting CAR-T products are typically preferred over CD22-targeting ones, and BCMA-targeting therapies are favored over GPRC5D-targeting ones.
Additionally, it’s important to consider the origin of the CAR-T cells (such as human-derived vs. mouse-derived) and the costimulatory signals used (e.g., 4-1BB vs. CD28). Different conditions may also influence the choice; for instance, lymphoma patients may be more suitable for CD28, while those with acute leukemia might benefit more from 4-1BB.
In the end, patients are advised to make an informed decision based on their medical history and the guidance of their doctors.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Complete Remission In Just Two Months! China’s CAR-T Therapy Brings New Hope For Lymphoma (DLBCL) Patients!
Complete Remission In Just Two Months! China’s CAR-T Therapy Brings New Hope For Lymphoma (DLBCL) Patients!
DLBCL
#Lymphoma #CAR_TCellTherapy #DLBCL#CancerHope #PatientStory
Lymphoma has long been regarded as a “synonym for death,” with its high incidence and recurrence rates striking fear into many. However, with the rapid advancement of medical technology, a revolutionary new therapy is changing this perception—CAR-T cell therapy. In recent years, China has made significant progress in this field, offering lymphoma patients a new ray of hope.
Recently, exciting news from China has garnered widespread attention. At a top cancer treatment center in the country, a patient with advanced diffuse large B-cell lymphoma (DLBCL) experienced a complete elimination of tumor cells just two months after receiving China’s CAR-T cell therapy. This demonstrates the extraordinary potential of CAR-T therapy in treating hematologic malignancies.
### A Breakthrough in Reversing Cancer: From Despair to Hope
Ms. Li from Zhuhai, China, was diagnosed in 2022 with diffuse large B-cell lymphoma (high-grade “double-hit” subtype), a rapidly progressing and challenging type of lymphoma with a high recurrence rate. It is considered one of the most aggressive forms of malignant lymphoma. Over the two years following her diagnosis, Ms. Li underwent various treatments, including chemotherapy and targeted therapy, but her condition remained uncontrolled. In early 2024, her disease worsened rapidly, making her battle against cancer even more difficult.
At this critical moment, Ms. Li sought help from the Advanced Medicine in China team. The experts quickly held a consultation and developed a personalized comprehensive treatment plan centered around CAR-T cell therapy.
### CAR-T Therapy in China: A Game Changer in Cancer Treatment
CAR-T therapy is a form of gene-engineered immunotherapy that involves modifying a patient’s own T cells to enable them to accurately target and eliminate cancer cells. This therapy not only offers strong targeting and potent effects but also significantly reduces the likelihood of recurrence. Particularly in China, where CAR-T technology has matured, more and more patients are benefiting from this innovative treatment.
One month after receiving CAR-T therapy, Ms. Li’s follow-up examination showed that all tumor cells in her body had been completely eradicated, achieving metabolic complete remission (mCR). Five months after her discharge, a further enhanced whole-body CT scan confirmed that she remained in complete remission (CR).
### The International Impact of CAR-T Therapy in China
Ms. Li’s rapid recovery from advanced diffuse large B-cell lymphoma (DLBCL) within just two months is not only a personal victory but also highlights China’s leading position in the field of CAR-T cell therapy. Through a combination of independent research and clinical applications, China is quickly emerging as a global leader in innovative cancer treatments.
As more success stories like Ms. Li’s emerge, China’s CAR-T cell therapy is gradually gaining international recognition, bringing hope to more patients with advanced cancer. China’s CAR-T technology, with its exceptional treatment outcomes, is shaping the future of cancer treatment.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #ChinaMedicalAdvances #Immunotherapy #CancerBreakthrough #Hematology #CancerResearch #AdvancedMedicine #CompleteRemission #CAR_TInnovation #HopeForCancerPatients #MedicalRevolution
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s CAR-T Cell Therapy: Leading a New Revolution in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma (MCL)
MCL
#CARTCellTherapy #MantleCellLymphoma #RelapsedMCL #RefractoryMCL #Hematology #MCL
Mantle Cell Lymphoma (MCL), a rare and complex subtype of non-Hodgkin’s lymphoma, exhibits both aggressive and indolent characteristics. Since MCL patients are usually diagnosed at an advanced stage, often with poor prognostic factors, traditional treatments such as chemotherapy and immunotherapy have brought survival benefits to some patients. However, most still face disease relapse or progression, particularly those with relapsed/refractory (r/r) MCL, where treatment poses significant challenges. For a long time, treatment options for MCL have been limited, making it difficult to achieve long-term remission or cure, highlighting the need for breakthroughs.
Chinese CAR-T Cell Therapy: Offering Hope for Relapsed/Refractory MCL With the rapid development of biotherapeutics, Chinese CAR-T cell therapy has emerged as a breakthrough innovation in lymphoma treatment. Since the approval of the world’s first CAR-T product in 2017, China has made significant progress in CAR-T research and application, especially in treating r/r MCL, where CAR-T therapy has shown excellent efficacy. CAR-T therapy not only significantly improves patient remission rates but also offers new survival opportunities for high-risk patients with poor prognoses.
Efficacy: In recent years, multiple international and Chinese clinical studies have confirmed the efficacy of CAR-T cell therapy in patients with relapsed/refractory MCL. Clinical data from China have also demonstrated outstanding results. In August 2024, the Chinese CAR-T product Relmacabtagene Autoleucel, a CD19-targeted CAR-T cell therapy, was approved for its third indication, treating adult patients with relapsed/refractory MCL (r/r MCL). Clinical data showed that Relmacabtagene Autoleucel achieved an overall response rate of 81.4%, with a complete response rate of 67.8%. The median progression-free survival (PFS) was 13 months, and the median overall survival (OS) was 19.5 months. These data further prove that Chinese CAR-T cell therapy not only has high efficacy in r/r MCL patients but also provides lasting survival benefits.
Side Effect Management: Despite its remarkable efficacy, CAR-T therapy is associated with certain side effects, such as cytokine release syndrome (CRS) and neurotoxicity (NT). However, with the continuous optimization of treatment technologies and accumulated experience in China, the incidence of side effects has been effectively controlled. In treating relapsed/refractory MCL patients, Chinese medical teams have been able to limit the occurrence of grade ≥3 CRS and NT to 6.8% in clinical practice. This lower toxicity makes CAR-T therapy safer in clinical applications, offering a new option for patients who cannot tolerate traditional treatments. Particularly for those who are resistant to Bruton’s tyrosine kinase inhibitors (BTKi) or ineligible for autologous hematopoietic stem cell transplantation, Chinese CAR-T therapy provides a gentler and effective treatment option.
Indications: The following groups of patients can benefit from Chinese CAR-T cell therapy:
-
Patients with relapsed/refractory MCL (r/r MCL)
-
MCL patients who do not respond to conventional treatments
-
Patients with poor prognostic factors (TP53 mutation, Ki67≥30%, blastoid MCL, pleomorphic MCL, POD24)
-
Patients previously exposed to BTKi or resistant/relapsed/refractory MCL
-
High-risk patients unsuitable for transplantation who cannot achieve good remission
Conclusion: With the widespread application of Chinese CAR-T therapy globally, more MCL patients, both domestic and international, are able to achieve deep remission and long-term survival. This not only marks a significant advancement in China’s hematological cancer treatment but also signifies that Chinese CAR-T cell therapy is leading a new transformation in the treatment of relapsed/refractory lymphoma worldwide.
🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #Immunotherapy #CancerResearch #Chinesemedicalbreakthrough #LymphomaTreatment #Oncology #Biotherapy #CancerInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
At which stage of treatment is the best time to choose CAR-T therapy?
At which stage of treatment is the best time to choose CAR-T therapy?
CAR-T therapy is often used as a last resort, but it should be introduced earlier for better outcomes. Early use, even as a frontline or 1.5-line treatment, could dramatically increase patient cure rates.
Tumor cells are highly adaptable and intelligent, learning to evade treatments over time. Treating tumors early, before they become stronger, is crucial.
CAR-T should not be considered a “last resort” in treatment, as waiting too long may reduce its effectiveness. It’s better to “kill the tumor when it’s young” before it becomes more resilient and difficult to eliminate.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!
Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!
**Patient Story – Oleg’s Cancer Journey:**
Today, we share the story of a 46-year-old patient from Russia named Oleg. Oleg was diagnosed with follicular lymphoma and, after multiple rounds of chemotherapy, achieved complete remission. Unfortunately, the disease relapsed, with several enlarged lymph nodes appearing in his abdomen and other areas. Faced with this resurgence, Oleg was determined not to give up and decided to seek new treatment options to improve his quality of life.
**Tailor-Made CAR-T Treatment Plan:**
After extensive research, Oleg contacted us and connected with lymphoma experts from our Advanced Medicine in China team. Through video consultations and detailed discussions, he decided to pursue CAR-T cell therapy. With confidence in the potential of Chinese CAR-T therapy, Oleg and his family traveled thousands of miles to China to begin his CAR-T treatment journey.
Given Oleg’s high tumor burden and relapse after chemotherapy, the Chinese medical team customized a bridging therapy for him, combining targeted drugs with low-dose radiotherapy to reduce the tumor burden and improve the immune environment. Special care was taken when designing the radiotherapy plan, as Oleg still had fertility concerns. The team created a personalized treatment plan that balanced safety and effectiveness. During the treatment process, Oleg experienced almost no significant side effects, demonstrating excellent treatment compliance and tolerance. He maintained a strong relationship of trust and communication with the medical team.
**Complete CR – A New Life After Treatment**
Oleg’s CAR-T cell infusion process went smoothly. Despite a history of migraines, he only experienced mild headaches and low-grade fever after the treatment. Under the meticulous care of the treatment team, the CAR-T cells demonstrated strong anti-tumor effects, with minimal side effects. For a patient with a high tumor burden, he only developed grade 1 cytokine release syndrome (CRS), and his blood counts began to recover about a week after the infusion. Overall, he remained in good condition.
Fifteen days after the CAR-T infusion, an abdominal ultrasound showed significant shrinkage of the enlarged lymph nodes. Three months later, a PET-CT scan brought even more surprising news—Oleg’s tumors had completely disappeared, and his response was evaluated as a complete remission (CR). This meant that Oleg had beaten cancer!
Today, Oleg is doing better and better, running daily. He is especially grateful for the support and care provided by the Advanced Medicine in China team and the Chinese experts. Despite being far from home, he never felt inconvenienced during his treatment in China. The doctors and nurses not only communicated with him patiently but also provided significant help in his daily life.
**Why Choose CAR-T Treatment in China?**
CAR-T therapy has shown remarkable efficacy in treating relapsed and refractory follicular lymphoma, with clinical data showing an objective response rate (ORR) of over 90% and a median duration of response exceeding three years! Oleg’s case is a testament to China’s advanced medical technology. Traditional chemotherapy tends to lose effectiveness after repeated treatments, while CAR-T therapy offers the possibility of curing diseases like follicular lymphoma, which were previously considered incurable.
For patients like Oleg, who seek a high-quality life, China’s CAR-T therapy is bringing new hope. 
**World-Class – China’s CAR-T Indications and Beyond**
Today, China’s CAR-T is not only actively involved in global research but is also leading many developments in the CAR-T field. For patients like Oleg with follicular lymphoma, only China and the U.S. have approved CAR-T products targeting this condition. However, China’s CR rate is notably higher.
Currently, China offers the most extensive range of CAR-T indications, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) for first-line, second-line, or third-line treatment failures or relapse; relapsed follicular lymphoma (FL) after second-line treatment; mantle cell lymphoma (MCL) with multiple treatment failures; unspecified DLBCL; large B-cell lymphoma transformed from FL; primary mediastinal large B-cell lymphoma; and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CART #CancerTreatment #AdvancedMedicineInChina #Lymphoma #FollicularLymphoma #CancerRemission #MedicalTourism #ChinaCare #HealingJourney #CancerFree #Immunotherapy #GlobalHealthcare
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Why Are More and More International Patients Coming to China for CAR-T Cell Therapy?
Why Are More and More International Patients Coming to China for CAR-T Cell Therapy?
CARTtherapy
#CARTtherapy #InternationalPatient #CART #Multiplemyeloma #lymphoma #leukemia
In recent years, CAR-T cell therapy, as an innovative cancer treatment, has rapidly gained widespread attention globally. China, as a leading country in the CAR-T treatment field, has attracted an increasing number of patients from Europe and Asia due to its advanced technology, high-quality medical resources, and relatively lower treatment costs. So, why are more international patients choosing to come to China for CAR-T treatment? Here are some key reasons worth noting:
### 1. **Advanced CAR-T Treatment Technology**
Over the past decade, China has made tremendous strides in medical research, particularly in the field of cancer immunotherapy. Not only has China successfully developed various CAR-T therapies, but it has also built a comprehensive treatment protocol and safety monitoring system to ensure efficient and safe treatment for patients. Additionally, China has accumulated extensive experience in managing treatment-related side effects, such as CRS (Cytokine Release Syndrome) and neurotoxicity.
Currently, more than 50% of the world’s clinical trials for CAR-T therapy are conducted in China. Of the 11 CAR-T products already on the global market, five are from China. These include products for multiple myeloma (BCMA CAR-T), diffuse large B-cell lymphoma (CD19 CAR-T), and leukemia. Compared to similar products in the U.S. for multiple myeloma, China’s CAR-T products are not only fully humanized but also boast the highest complete remission rates among all available products, reaching 82.4%. The CR data for China’s lymphoma and leukemia CAR-T products are also impressive, at 77.6% and 82.1%, respectively.
### 2. **International Certification and Clinical Trial Opportunities**
Several hospitals and research institutions in China have gained international recognition for their CAR-T therapies. Patients can choose between commercial CAR-T treatments or participate in clinical trials. For some CAR-T treatments that have not yet been approved or are hard to access in Europe or Asia, patients can receive these cutting-edge therapies in China earlier.
Just a few days ago, Chinese scholars’ research on universal CAR-T cell therapy was featured on the cover of *Nature*. Various other studies on Chinese CAR-T therapies are frequently published in major medical journals. For example, a Chinese medical team published a study on dual-target CAR-T in *JAMA Oncology*, showing a 100% stringent complete remission (sCR) rate in high-risk multiple myeloma patients. Additionally, a research team from Zhejiang, China, published clinical data in *Cell Discovery*, highlighting the breakthrough of the fourth-generation anti-CD19 CAR-T cell therapy in treating relapsed/refractory large B-cell lymphoma with exceptional anti-tumor capabilities.
### 3. **Relatively Low Treatment Costs**
Compared to the million-dollar treatment costs in Western countries, CAR-T treatment in China is relatively affordable, often costing just 1/5 to 1/7 of the price in the U.S. For instance, the cheapest CAR-T product for multiple myeloma in the U.S. costs $420,000, and when including hospitalization and other expenses, the total cost can reach around $700,000. In contrast, similar Chinese products, with equal or even better effectiveness, cost only $160,000, and hospitalization and other fees are much lower, often under $10,000. Some treatment options are available for just a few tens of thousands of dollars, and in certain cases, treatment is even completely free.
Patients from Europe and Asia can receive world-class CAR-T therapy in China at a much lower cost, providing an affordable option for those who find the high costs of treatment elsewhere prohibitive. Moreover, a range of one-stop medical services, including hospital visits, translation assistance, transportation, accommodation, and even family care, can significantly enhance the patient experience for international patients.
### 4. **World-Class Expert Teams**
China is home to a group of internationally renowned oncology and immunotherapy experts who have extensive clinical experience and academic achievements in hematological cancers and CAR-T therapy. Patients receive personalized treatment plans designed by leading experts, ensuring that each treatment is precisely tailored to their specific condition, maximizing effectiveness and minimizing risks.
For example, Professor Huang Xiaojun, Director of the Institute of Hematology at Peking University, is one of the world’s pioneers in haploidentical transplantation, having developed China’s haploidentical hematopoietic stem cell transplantation model. His innovative approach has increased the 3-year survival rate of leukemia patients receiving haploidentical transplants from around 20% to approximately 70%, earning him the Distinguished Service Award from the Center for International Blood and Marrow Transplant Research.
### 5. **Efficient and Convenient Medical Services**
China has implemented a 144-hour visa-free transit policy for citizens of 54 countries and mutual visa exemptions with 24 countries. This is a major benefit for international patients seeking treatment in China. Moreover, China’s healthcare system is known for its efficiency and convenience, especially in treating major diseases. Appointment wait times are short, and there is minimal delay in receiving treatment. A “super green channel” is also available for international patients, ensuring quick diagnosis and treatment planning. From initial consultation to online meetings with specialists, the process typically takes less than a week, with hospital admission and treatment beginning within another week.
Compared to the long waiting periods in other countries, China’s efficient medical services significantly improve treatment success rates and patient satisfaction. CAR-T therapy, in particular, is known for its high efficiency. There was an international patient who went from initial consultation to complete remission and a safe return home in less than a month—a remarkable achievement considering CAR-T is a “living” drug that must be custom-prepared using the patient’s own blood cells.
### 6. **Abundant Success Stories**
Many international patients who have received CAR-T therapy in China have achieved remarkable results, with their cancers being effectively controlled or even cured. These success stories not only boost confidence among patients worldwide but also attract more people to China for treatment. By sharing these stories, more patients learn about China’s advantages in CAR-T therapy and choose it as their treatment destination.
For instance, Ethan, a patient from Singapore, achieved complete remission just four weeks after CAR-T treatment and has since recovered very well. There is also the story of a Russian patient with high-risk, late-stage multiple myeloma who received efficient treatment in China at a much more reasonable cost and with a faster treatment process.
### 7. **Conclusion**
In conclusion, as China continues to enhance its technological capabilities in CAR-T cell therapy, more and more patients from around the world are choosing to come to China for this cutting-edge cancer treatment. With its advanced medical technology, international services, and relatively lower treatment costs, China is becoming an important destination for cancer patients seeking treatment. If you or a loved one is searching for innovative cancer treatment options, consider CAR-T therapy in China for a chance at recovery!
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can contact us for preliminary evaluation!
WhatsApp: +8613717959070
Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CellTherapy #CancerTreatment #Immunotherapy #HealthcareInnovation #MedicalTourism #ChinaHealthcare #CancerSurvivor #PatientStories #MedicalAdvancements #AffordableHealthcare #PersonalizedMedicine #GlobalHealth #HealthJourney #Oncology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment
Chinese Medical Team’s Fourth-Generation CAR-T Therapy: Revealing New Hope for B-Cell Lymphoma Treatment
Lymphoma
#CART #CellDiscovery #Lymphoma #BCellLymphoma #RRLBCL #IL7 #CCL19
In recent years, China has made significant progress in medical innovation, especially in the field of Chimeric Antigen Receptor T-cell (CAR-T) therapy, dramatically changing the landscape of treatment for malignant blood cancers. Recently, a team of medical professors from Zhejiang, China, released the results of a clinical trial demonstrating the breakthrough effectiveness of fourth-generation anti-CD19 CAR-T cell therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The study, published in the renowned journal *Cell Discovery* (“Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma”), sheds light on this innovative approach.
**New Highlights of CAR-T Therapy**
Traditional anti-CD19 CAR-T cell therapy has already shown excellent efficacy in treating blood cancers like R/R LBCL, but tumor relapse remains a significant challenge. To address this, Chinese researchers have developed a new fourth-generation CAR-T cell therapy that co-expresses two cytokines, IL-7 and CCL19. These cytokines enhance the activity of immune cells, improving CAR-T cells’ anti-tumor effects and extending patient survival.
**Efficacy and Potential**
The Chinese medical team included 39 patients, aged 29 to 73, in this study. They received a single infusion of the fourth-generation anti-CD19 CAR-T cells co-expressing IL-7/CCL19. The results showed that within three months of treatment, the overall response rate (ORR) reached 79.5%, with a complete response rate (CR) of 56.4%. This therapy also demonstrated a notable long-lasting effect, with a median progression-free survival (PFS) of 13 months, and an estimated two-year overall survival rate (OS) of 53.8%.
The study found that the expansion of CAR-T cells in the blood and plasma levels of IL-7/CCL19 were closely associated with clinical outcomes. Higher CAR-T cell expansion and peak concentrations of IL-7/CCL19 were linked to better overall survival (OS), further confirming that this combination can enhance CAR-T cells’ anti-tumor potential.
**Why Is This Study So Important?**
The introduction of this new CAR-T therapy in China marks a significant leap forward in cancer treatment. It not only induces long-lasting remission but also significantly extends patient survival, with manageable safety, offering new hope to patients facing resistant blood cancers. China’s rapid advancements in CAR-T technology showcase its growing influence in the global biotechnology sector.
This groundbreaking research not only solidifies China’s important position in medical innovation but also lays the foundation for future development and application of more CAR-T therapies, potentially bringing revolutionary changes to cancer treatment worldwide.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CAR_Therapy #CancerTreatment #MedicalInnovation #BCellLymphoma #ChinaBiotech #Immunotherapy #FourthGenerationCAR_T #BloodCancer #CytokineTherapy #OncologyBreakthrough #CellDiscovery #CancerResearch #TumorImmunology #PatientSurvival #Hematology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China？
# What Types of Lymphoma Patients Are Suitable for CAR-T Treatment in China?
Lymphoma